Impact of Migration History and Social Conditions on the Immuno-virological Control of HIV in Migrants in France

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07691424

Acronym

PrimoAVIH

Enrollment

150

Registered

2026-07-08

Start date

2026-07-15

Completion date

2030-02-15

Last updated

2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV - Human Immunodeficiency Virus, Migrants, Socio-economic Status

Keywords

HIV, socio-economic status, vulnerability, immuno-virological status, migrants

Brief summary

Migrants living with HIV - whether the infection was diagnosed in their country of origin or in France- frequently experience vulnerabilities related to their migration trajectories and often face socioeconomic and administrative instability upon arrival . The primary outcome of this study is to compare the immunovirological efficacy of antiretroviral therapy among migrants living with HIV patients according to their social and administrative status.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (≥18 years of age); * Migrant patients (i.e., individuals who entered France for the first time from another country) receiving care at Clermont-Ferrand University Hospital between January 1, 2010, and December 31, 2022, whose HIV infection was either known at the time of their arrival in France or diagnosed within 12 months after their arrival in France. Non-inclusion Criteria: * Patients who declined to participate in the study; * Patients who do not speak French and for whom no interpretere was available * Adults subject to a legal protection measure (i.e., under guardianship, curatorship, or judicial protection)

Design outcomes

Primary

Measure	Time frame	Description
HIV immuno-virological status	Submission to the Research Ethics Committee (REC): February 2026 REC approval: May 2026 Study initiation : July 2026 Recruitment period: 18 months Total study duration: 30 months Estimated study completed : january 2029	To compare the immuno-virological efficacy of antiretroviral therapy according to the social and administrative status of HIV-infected migrants

Countries

France

Contacts

CONTACTLise Laclautre

promo_interne_drci@chu-clermontferrand.fr+33473754963

PRINCIPAL_INVESTIGATORAida ZAGHDOUDI

University Hospital, Clermont-Ferrand

Outcome results